Abstract
In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.
| Original language | English (US) |
|---|---|
| Article number | 25 |
| Journal | Current treatment options in oncology |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2019 |
Fingerprint
Keywords
- Controversy
- IDH mutation
- Low-grade glioma
- PCV
- Temozolomide
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Cite this
Controversies in the Therapy of Low-Grade Gliomas. / Carabenciov, Ivan D.; Buckner, Jan Craig.
In: Current treatment options in oncology, Vol. 20, No. 4, 25, 01.04.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Controversies in the Therapy of Low-Grade Gliomas
AU - Carabenciov, Ivan D.
AU - Buckner, Jan Craig
PY - 2019/4/1
Y1 - 2019/4/1
N2 - In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.
AB - In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.
KW - Controversy
KW - IDH mutation
KW - Low-grade glioma
KW - PCV
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=85062975797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062975797&partnerID=8YFLogxK
U2 - 10.1007/s11864-019-0625-6
DO - 10.1007/s11864-019-0625-6
M3 - Review article
VL - 20
JO - Current Treatment Options in Oncology
JF - Current Treatment Options in Oncology
SN - 1527-2729
IS - 4
M1 - 25
ER -